Rapid Influenza Diagnostic Tests (RIDT) Market by Manufacturers, Regions, Type and Application Forecast to 2030 Global Market Insights add New Global Rapid Influenza Diagnostic Tests (RIDT) Market report provides in-depth information about market overview, top vendors, Key market highlights, product types, market drivers, challenges, trends, Rapid Influenza Diagnostic Tests (RIDT) industry landscape, size and forecast, five forces analysis, Key leading countries/Region. The rapid influenza diagnostic tests (RIDT) market is expected to grow significantly by 2030 owing to increasing prevalence of influenza. In addition, surging necessity for early diagnosis, along with rising popularity of rapid testing, is set to further boost market growth through the forecast period. Browse key industry insights spread across 80 pages with 69 market data tables & 12 figures & charts from the report, “Rapid Influenza Diagnostic Tests Market Size By End-use (Hospitals, Diagnostics Centers, Research Laboratories), Industry Analysis Report, Regional, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/rapid-influenza-diagnostic-tests-ridtmarket Notably, lack of skilled professionals and stringent lockdown regulations imposed during the COVID-19 outbreak posed a threat to market growth However, with the burgeoning number of cases and high risk of exposure to COVID-19 in hospital settings, at-home testing gained massive popularity. Thus, rising consumer interest in at-home testing kits, coupled with soaring demand for telemedicine for influenza infection diagnosis, has positively impacted the product landscape of the rapid influenza diagnostic tests (RIDT) market. Furthermore, major players in the industry have been focusing on research and development activities to introduce technologically advanced rapid influenza tests. In addition, strategic partnerships and acquisitions have also aided in business expansion. For instance, in October 2020, Quidel Corporation, a leading manufacturer of diagnostic healthcare products, received EUA (Emergency Use Authorization) from the U.S. FDA (Food and Drug Administration) for marketing its Sofia 2 Flu + SARS Antigen FIA, a rapid point-ofcare test used in conjunction with Sofia 2 Fluorescent Immunoassay Analyzer to differentiate nucleocapsid protein antigen from SARS-CoV-2 and influenza A and B via direct nasal (NS) and nasopharyngeal (NP) swab samples in potential COVID-19 patients.
© 2022 All Rights Reserved
www.gminsights.com